Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change.
about
Combination medical treatment for primary open angle glaucoma and ocular hypertension: a network meta-analysisWhere does selective laser trabeculoplasty stand now? A reviewMedical Management of Glaucoma in the 21st Century from a Canadian PerspectiveShort-Term Moderately Elevated Intraocular Pressure Is Associated With Elevated Scotopic Electroretinogram ResponsesBlindness and Glaucoma: A Multicenter Data Review from 7 Academic Eye ClinicsEfficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.Rates of retinal nerve fibre layer thickness change in glaucoma patients and control subjectsTransplantation of mesenchymal stem cells promotes tissue regeneration in a glaucoma model through laser-induced paracrine factor secretion and progenitor cell recruitment.Efficacy and tolerability of fixed-combination bimatoprost/timolol versus fixed-combination dorzolamide/brimonidine/timolol in patients with primary open-angle glaucoma or ocular hypertension: a multicenter, prospective, crossover study.Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.Risk Factors for Primary Open Angle Glaucoma (POAG) Progression: A Study Ruled in TorinoSafety and Efficacy of Adding Fixed-Combination Brinzolamide/Timolol Maleate to Prostaglandin Therapy for Treatment of Ocular Hypertension or Glaucoma.Quality of life in glaucoma patients after selective laser trabeculoplastySelective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients.Prior rates of visual field loss and lifetime risk of blindness in glaucomatous patients undergoing trabeculectomy.A combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertension.Rates of visual field progression in clinical glaucoma careAre practical recommendations practiced? A national multi-centre cross-sectional study on frequency of visual field testing in glaucoma.Efficacy of Bimatoprost Plus Timolol Fixed Combination in Open Angle Glaucoma Patients Previously Treated with Dorzolamide Plus Timolol Fixed Combination.Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma.Significant Glaucomatous Visual Field Progression in the First Two Years: What Does It Mean?A combined analysis of four observational studies evaluating the intraocular pressure-lowering ability and tolerability of bimatoprost 0.01% in patients with primary open-angle glaucoma or ocular hypertensionProgression of visual field in patients with primary open-angle glaucoma - ProgF study 1.Comparison of Three Parametric Models for Glaucomatous Visual Field Progression Rate Distributions.Effect of intraocular pressure on the Bayesian estimation of rates of visual field progression in glaucoma.Risk factors and long term progression in open angle glaucoma patients.Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial.Baerveldt tube implantation following failed deep sclerectomy versus repeat deep sclerectomy.Distribution of IOP measured with an air puff tonometer in a young population.What rates of glaucoma progression are clinically significant?Six-Month Outcomes of Goniotomy Performed with the Kahook Dual Blade as a Stand-Alone Glaucoma Procedure
P2860
Q24192958-3557030B-8E38-4D5B-BB4B-DA658DD94998Q26751116-C49936E0-0AF4-454A-836B-4CF3C1EC3546Q28074316-EF00A470-F1F8-4546-B5E8-1370079E6783Q28393364-E0B946F3-996E-42B9-A6BF-CD10D23009FFQ30000044-69E20BB7-2A7A-4927-A5D3-9C9BCE278AE0Q34253481-83D8A95F-0A4A-4CC1-A810-B75175171A5AQ34451569-DF869F79-3097-45DD-8615-A6A8BDA89B05Q34621134-74722129-FE62-4EBA-8F15-39BAD284BC56Q34981291-64937D23-1667-4AA6-AB3C-94EBEBA82791Q35681331-9CDCA558-043C-4E3F-82B3-56EC76A127E3Q36062102-07615FFE-C6A3-40C5-8CC8-5F8420321260Q36162811-B073D7C4-9790-454E-8A62-6C6D691B375EQ36382245-1846AFEA-5569-4AB9-8ADD-91C2A5F9E905Q36411219-4BB0897E-5DA8-4EF8-9F78-882E7A824A85Q36750376-D89E7915-7C85-4EE9-83EA-28C745C548ADQ36958046-A667A997-3BE5-4E07-B912-95DE8B3A7CBFQ37233278-27BD6B90-F773-4F75-A7ED-5A43563C0156Q38101312-98B74313-BE5F-4325-858E-C61CB8E70CD0Q38817821-F45539B7-4949-423A-AE37-A9081BEBAA57Q38988955-B1A0D63D-37BC-4020-97B0-B9B08ABB7D92Q39185172-38A80DE8-4B48-4C64-B113-7B89C0C385ABQ39831161-07A48164-8EBB-4E22-A55D-4C27E4CEC7CCQ40814918-249DC315-8D7D-458D-9735-55440BC8B6A0Q41819867-D0F8298B-0E70-446D-BCC7-B179AC14E0FAQ43229855-7A530F90-7D14-4D57-BC11-C762B74127ECQ47104934-0D17DEA5-294B-4FBC-8C48-4B998949C952Q51499423-64352F7C-EA7F-43E6-8163-63EA8116E604Q51664554-6F47B0DC-DB98-4E8A-8553-F3F6A0382528Q54959911-1C6062A4-8CD4-4CEB-8020-1F22357DC3F2Q54972682-7B24E4DA-4579-4746-9CE8-C9F9538C9E14Q57467856-A79F9118-ED60-4DB0-8A0D-D6E6147AD091
P2860
Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Canadian Glaucoma Study: 3. Im ...... rates of visual field change.
@en
type
label
Canadian Glaucoma Study: 3. Im ...... rates of visual field change.
@en
prefLabel
Canadian Glaucoma Study: 3. Im ...... rates of visual field change.
@en
P2093
P1433
P1476
Canadian Glaucoma Study: 3. Im ...... rates of visual field change.
@en
P2093
A Gordon Balazsi
Balwantray C Chauhan
Canadian Glaucoma Study Group
Frederick S Mikelberg
Graham E Trope
Marcelo T Nicolela
Mark R Lesk
Raymond P LeBlanc
P304
P356
10.1001/ARCHOPHTHALMOL.2010.196
P407
P50
P577
2010-08-09T00:00:00Z